1. Home
  2. PRLD vs BGSF Comparison

PRLD vs BGSF Comparison

Compare PRLD & BGSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRLD
  • BGSF
  • Stock Information
  • Founded
  • PRLD 2016
  • BGSF 2007
  • Country
  • PRLD United States
  • BGSF United States
  • Employees
  • PRLD N/A
  • BGSF N/A
  • Industry
  • PRLD Medicinal Chemicals and Botanical Products
  • BGSF Professional Services
  • Sector
  • PRLD Health Care
  • BGSF Consumer Discretionary
  • Exchange
  • PRLD Nasdaq
  • BGSF Nasdaq
  • Market Cap
  • PRLD 63.3M
  • BGSF 66.0M
  • IPO Year
  • PRLD 2020
  • BGSF N/A
  • Fundamental
  • Price
  • PRLD $1.04
  • BGSF $5.93
  • Analyst Decision
  • PRLD Buy
  • BGSF
  • Analyst Count
  • PRLD 3
  • BGSF 0
  • Target Price
  • PRLD $5.33
  • BGSF N/A
  • AVG Volume (30 Days)
  • PRLD 408.0K
  • BGSF 14.7K
  • Earning Date
  • PRLD 11-06-2024
  • BGSF 11-06-2024
  • Dividend Yield
  • PRLD N/A
  • BGSF 10.02%
  • EPS Growth
  • PRLD N/A
  • BGSF N/A
  • EPS
  • PRLD N/A
  • BGSF N/A
  • Revenue
  • PRLD $3,000,000.00
  • BGSF $281,656,000.00
  • Revenue This Year
  • PRLD N/A
  • BGSF N/A
  • Revenue Next Year
  • PRLD N/A
  • BGSF $9.60
  • P/E Ratio
  • PRLD N/A
  • BGSF N/A
  • Revenue Growth
  • PRLD N/A
  • BGSF N/A
  • 52 Week Low
  • PRLD $1.00
  • BGSF $5.83
  • 52 Week High
  • PRLD $6.80
  • BGSF $10.74
  • Technical
  • Relative Strength Index (RSI)
  • PRLD 21.69
  • BGSF 19.26
  • Support Level
  • PRLD $1.14
  • BGSF $7.00
  • Resistance Level
  • PRLD $1.36
  • BGSF $7.24
  • Average True Range (ATR)
  • PRLD 0.11
  • BGSF 0.32
  • MACD
  • PRLD 0.03
  • BGSF -0.17
  • Stochastic Oscillator
  • PRLD 7.53
  • BGSF 5.03

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

About BGSF BGSF Inc.

BGSF Inc is a provider of workforce solutions operating primarily in the U.S. across two segments: Property Management and Professional. In the Property Management segment, BGSF offers office and maintenance talent to clients, facilitating their staffing needs with short-term and consulting solutions. The Professional segment specializes in IT, offering skilled professionals in SAP, Workday, and other areas to Fortune 500 companies and consulting firms nationwide. BGSF's workforce services include on-demand assignments, consulting, and managed solutions, allowing clients to flexibly manage their workforce needs. With a focus on converting fixed personnel costs to variable expenses, BGSF enables companies to effectively address fluctuations in demand while optimizing costs.

Share on Social Networks: